Reader View AI Reader View Syndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial www.investing.com · October 12, 2026 · 20:04 Paywall detected This article has a paywall The publisher blocks direct access to this article. Generate with AI Open link